LONDON, February 3, 2016 /PRNewswire/ --
BTG plc (LSE: BTG), a global specialist healthcare company, and
Royal Philips (NYSE: PHG; AEX:
PHIA), announced today a significant milestone in their
collaboration with the treatment of the first liver cancer patient
with LC Bead LUMI™ in conjunction with Philips Live Image Guidance,
targeting a hypervascular tumor with the goal to block blood flow
to achieve tumor necrosis.
(Logo:
http://photos.prnewswire.com/prnh/20160203/329110LOGO )
(Logo:
http://photos.prnewswire.com/prnh/20160203/329111LOGO )
Liver cancer is the second leading cause of cancer deaths in the
world[1], and one of the most
challenging to treat. Each year, more than 700,000 patients
worldwide are diagnosed with liver
cancer.[2] Interventional
embolization is an option for some patients with tumors that cannot
be removed by surgery.
The first patient treated signals the next stage in
commercializing next generation embolic beads, which can be
visualized during interventional procedures, allowing enhanced
visualization to evaluate completeness of tumor treatment. As a
result of the collaboration between BTG and Philips, for the first
time doctors will be able to see rather than assume the location of
the LC Bead LUMI™, in order to deliver their treatment with more
confidence when treating liver cancer.
"The aim with this new radiopaque embolic bead and visualization
technology is to provide clinicians like me the ability to make
real-time adjustments while conducting the embolization procedure,
so that we can optimize patients' treatment and hopefully improve
targeting accuracy," said Bradford
Wood, M.D., Director of the NIH Center for Interventional
Oncology* and Chief of Interventional Radiology. "It is reassuring
for the clinician and the patient to know that the treatment was
delivered exactly where it was aimed, and where it was needed.
Treating the first patient using LC Bead LUMI™ in combination with
dedicated Philips 2D X-ray and 3D CBCT image guidance is a
milestone in our public-private partnership with both of our
industry research partners. The imaging of the beads during this
first procedure was exquisite and provided valuable
information."
By enabling visualization of beads during an embolization
procedure, LC Bead LUMI™ will help embolization technology achieve
its full potential. LC Bead LUMI™ has been developed with
revolutionary radiopacity technology in collaboration with Philips
that enables real-time visualization of bead location during
embolization. LC Bead LUMI™, supported by Philips Live Image
Guidance, has the potential to offer interventional radiologists
more control, allowing enhanced visualization to evaluate the
completeness of tumor treatment and end-point determination.
"BTG continues to advance its leadership in Interventional
Medicine by actively listening to our customers and providing
creative solutions to meet their clinical needs," said Peter Pattison, Interventional Oncology General
Manager, BTG. "Several years ago, we began scientific collaboration
with Philips to evaluate the benefits of better image-guided
therapy and this venture resulted in the ability to calibrate
Philips' imaging software to LC Bead LUMI™. The clinical impact of
the BTG / Philips collaboration is now helping interventional
radiologists and multi-disciplinary teams make enhanced treatment
decisions for patients with liver cancer."
Ronald Tabaksblat, Business Leader, Imaging Guided Therapy
Systems, Philips commented "Minimally-invasive therapy procedures
provide key benefits for healthcare systems and patients, and
intelligent image guidance is an essential part of these
procedures. We aim to continuously improve Image Guided Therapy and
our collaboration with BTG to provide enhanced visibility and
guidance during interventional embolization procedures is another
important milestone in this exciting journey to help deliver
excellent treatment and enhanced patient care."
LC Bead LUMI™ was cleared for clinical use in the US in
December 2015 after extensive
laboratory testing based on the clinical foundation of its
predicate device, LC Bead®.
BTG and Philips will showcase their advancements in
interventional oncology at the upcoming symposium on Clinical
Interventional Oncology (CIO), taking place Feb. 6 - 7 in Hollywood, FL. For information on BTG,
visit http://www.btg-im.com, and to learn more about Philips
integrated solutions for diagnostics and therapeutic oncology,
please visit http://www.philips.com/io.
* NIH does not endorse or recommend any commercial products,
processes, or services. The views and opinions of authors expressed
here do not necessarily state or reflect those of the US Government
or the NIH, and they may not be used for advertising or product
endorsement purposes.
About LC Bead
LUMI™
LC Bead LUMI™ is the first commercially
available radiopaque embolic bead cleared by the US Food & Drug
Administration (FDA) for the embolization of hypervascular tumors
and arteriovenous malformations (AVMs). LC Bead LUMI™ provides
visible confirmation of bead location during AVM procedure. The
lasting radiopacity of LC Bead LUMI™ means they will also be
visible in follow-up scans. To register for more information,
please visit: LCBeadLUMI.com
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local,
no company endeavors to do more than BTG Interventional Medicine to
help doctors in their quest to see more, reach further and treat
smarter. Our growing portfolio of Interventional Medicine products
is designed to advance the treatment of liver tumors, advanced
emphysema, severe blood clots, and varicose veins. To learn more
about BTG Interventional Medicine, please visit: btg-im.com.
About Royal
Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a diversified health and well-being company, focused on
improving people's lives through meaningful innovation in the areas
of Healthcare, Consumer Lifestyle and Lighting. Headquartered in
the Netherlands, Philips posted
2015 sales of EUR 24.2 billion and
employs approximately 104,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care,
acute care and home healthcare, energy efficient lighting solutions
and new lighting applications, as well as male shaving and grooming
and oral healthcare. News from Philips is located at
http://www.philips.com/newscenter
References:
1. World Health Organization (WHO). Cancer factsheet. Available
at: http://www.who.int/mediacentre/factsheets/fs297/en/. Last
accessed January 25, 2016.
2. American Cancer Society. What are the key statistics about
liver cancer?. Available at:
http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics.
Last accessed January 25, 2016.
SOURCE BTG and Philips